GeneCast Biotechnology Co., Ltd.
GeneCast Biotechnology Co., Ltd.
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma | Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Not stated | 2026-04-08 | NCT05479708 | |
| Adjuvant Pancreatic Therapy Guided by MRD | Pancreatic Adenocarcinoma Resectable | Recruiting | Not applicable | 2025-07-15 | NCT06966440 | |
| Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2025-07-11 | NCT04922853 | |
| CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm | Recruiting | Phase 2 | 2024-12-12 | NCT06242418 | |
| Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Phase 2 | 2023-09-26 | NCT05450029 | |
| CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 3 | 2023-01-26 | NCT05699746 | |
| Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Phase 3 | 2022-10-25 | NCT05244798 | |
| Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2022-08-31 | NCT05334277 | |
| Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Enrolling by invitation | Phase 3 | 2022-02-24 | NCT04762459 |